Informa
TIDES Europe: Oligonucleotide and Peptide Therapeutics

2025年11月11-13日
スイス、バーゼル、Congress Center Basel

Main Conference Day 2 - CET (Central European Time, GMT+01:00)

Main Conference Day 2 - CET (Central European Time, GMT+01:00)
06:30 - 07:3060 mins
Early Morning Fun Run
    07:30 - 08:0030 mins
    Morning Spotlight Presentation
    Continuous and Emerging Drying Process for Peptides and Oligonucleotides
    • Audrey Maudhuit - European Director, Fluid Air
    08:00 - 08:055 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    Chairpersons Remarks: Oligonucleotide Chemistry and Discovery
    • Troels Koch, PhD - Chief Technology Officer, MiNa Therapeutics
    08:00 - 08:055 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    Chairwoman's Remarks: Case Studies of Innovations and Efficiencies in Oligonucleotide CMC
    • Sonja Merkas, PhD - Founder, Creator and Doer, Livinovea
    08:00 - 08:055 mins
    Peptide Discovery to CMC
    Chairman’s Remarks: Peptide Chemistry and Discovery
    • Christian Becker, Ph.D. - Professor and Head of the Institute of Biological, University of Vienna
    08:05 - 08:3530 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    Future Directions for Medicinal Chemistry in the Field of Oligonucleotide Therapeutics
    • Jonathan Hall, PhD - Full Professor, ETH Zurich
    08:05 - 08:3530 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    Early and Late Phase Process Optimization of siRNA Manufacturing
    • Damian Ackermann, PhD - Principal Scientist, Novartis
    08:05 - 08:3530 mins
    Peptide Discovery to CMC
    Precision Synthesis in Peptide Chemistry: Programmable Site-Selectivity for Cysteine Modification
    • Kevin Neumann, PhD - Assistant Professor, Radboud University
    08:35 - 09:0530 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    Thermodynamics-guided Control of Off-target Interactions in Antisense Therapeutics
    • Tsuyoshi Yamamoto, PhD - CSO, Liid Pharmaceuticals
    08:35 - 09:0530 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    Synthesis Process Development and Manufacture of a 2’-N-methylacetamide Antisense Oligonucleotide
    • Thomas Pickel - Scientist II, Oligonucleotide Process Development, Biogen, USA
    08:35 - 09:0530 mins
    Peptide Discovery to CMC
    Therapeutic Modulation of Protein-Protein Interactions by Reactive Peptides
    • Nathalie Grob, PhD - Assistant Professor, ETH Zurich
    09:05 - 09:3530 mins
    Oligonucleotide Discovery, Preclinical and Clinical
    Exploring Novel Sulfamates Neutral Backbones Modalities with Enhanced Delivery
    • Afaf El-Sagheer, PhD - Assistant Professor, University of Southampton
    09:05 - 09:3530 mins
    Oligonucleotide Chemistry, Manufacturing & Controls
    Confirmation of the Identity of Stereopure Oligonucleotides
    • Keith Bowman - Vice President of Process Development, Wave Life Sciences
    09:05 - 09:3530 mins
    Peptide Discovery to CMC
    Development of a Selective Inhibitor of Human Factor XII and Its Use in Anticoagulation during Extracorporeal Membrane Oxygenation (ECMO) Treatment
    • David Craik, PhD - Professor of Biomolecular Structure, University of Queensland
    09:35 - 10:1540 mins
    Networking Refreshment Break in Poster and Exhibit Hall
    Networking Refreshment Break in Poster and Exhibit Hall
      09:45 - 09:5510 mins
      TIDES Talks in Poster and Exhibit Hall
      From Research to IND-Enabling Projects: Integrated Platform to Accelerate RNA Research
      • Yang Wang - Deputy Head of Molecular Biology Product Marketing, GenScript
      09:55 - 10:0510 mins
      TIDES Talks in Poster and Exhibit Hall
      Axolabs TIDES Talk
        10:15 - 10:4530 mins
        Oligonucleotide Discovery, Preclinical and Clinical
        RNA Activation: Small Nuclear RNAs as Novel Medicine
        • Mikko Turunen, PhD - Founder and CSO, RNatives Inc.
        10:15 - 10:4530 mins
        Oligonucleotide Chemistry, Manufacturing & Controls
        Considerations for Recycling of Acetonitrile in Oligonucleotide Manufacturing
        • Gresa Farmer - Chemical Development Scientist, Novo Nordisk
        10:15 - 10:4530 mins
        Peptide Discovery to CMC
        Development of All-D-peptides for the Treatment of Neurodegenerative Disorders
        • Philipp Buerling - CEO, Priavoid GmbH
        10:45 - 11:1530 mins
        Oligonucleotide Discovery, Preclinical and Clinical
        RES-010: An Antisense Oligonucleotide Targeting miR-22 for Metabolic Reprogramming in Obesity
        • Riccardo Panella - CSO and Scientific Founder, Resalis Therapeutics
        10:45 - 11:1530 mins
        Oligonucleotide Chemistry, Manufacturing & Controls
        Large-Scale Application of Dynamic Axial Compression Columns during Solid-Phase Oligonucleotide Synthesis to Reduce Solvent Volumes
        • Francis Ring - Director of Manufacturing & Operations, Ionis Pharmaceuticals
        10:45 - 11:1530 mins
        Peptide Discovery to CMC
        Harnessing Nature’s Biosynthetic Language for Next-Generation Macrocycles
        • Steven Schmitt, PhD - CEO and Co-Founder, Myria Biosciences AG
        11:15 - 11:4530 mins
        Oligonucleotide Discovery, Preclinical and Clinical
        ASO-Mediated Targeting of the Wisper lncRNA to Treat Cardiac Fibrosis
        • Daniel Blessing - CTO, HAYA Therapeutics
        11:15 - 11:4530 mins
        Oligonucleotide Chemistry, Manufacturing & Controls
        Panel Discussion
        • Sonja Merkas, PhD - Founder, Creator and Doer, Livinovea
        • Tobias Kapferer, PhD - Director and xRNA Network Lead, Novartis
        • Martin Olbrich, PhD - Head of Process Chemistry 3, F Hoffmann-La Roche Ltd.
        • Jale Muslehiddinoglu, PhD - Vice President of Strategic Innovation, ST Pharm
        11:15 - 11:4530 mins
        Peptide Discovery to CMC
        Development of Novel Anti-obesity Peptides Using StreaMLine - A Machine Learning-driven Peptide Drug Discovery Platform
        • Claudia Hjørringgaard, PhD - Principal Scientist, Gubra
        11:45 - 11:505 mins
        Transition to Spotlight Presentations
          Spotlight Presentations
          11:50 - 12:2030 mins
          Spotlight Presentation 1
          Delivering on RNAi Demand: Scaling RNA Therapeutics Sustainably with the ECO Synthesis™ Platform
          • Derek Gauntlett - Senior Director, ECO Process Development, Codexis
          11:50 - 12:2030 mins
          Spotlight Presentation 2
          ST Pharm's Journey as a Solution Provider for RNA-based Therapeutics: From Metric Ton Provider of ASOs and siRNAs to guide RNA, mRNA, circRNA and their Formulations
          • HJ Jung - Vice President, ST Pharm
          11:50 - 12:2030 mins
          Spotlight Presentation 3
          Agilent Scientific Briefing
            12:20 - 13:2565 mins
            Networking Luncheon in Poster and Exhibit Hall
            Networking Luncheon in Poster and Exhibit Hall
              12:40 - 12:5010 mins
              TIDES Talks in Poster and Exhibit Hall
              Building a Robust & Sustainable Process for Raw Material Supply: Enzymatic Synthesis of Nucleoside Quad Phosphates (NQPs)
              • Jonathan Dorigatti, PhD - Scientist II, ECO Process Development, Codexis
              12:50 - 13:0010 mins
              TIDES Talks in Poster and Exhibit Hall
              Attaching Novel Albumin Binders to Modulate Peptides Stability and Pharmacokinetics
              • Shahadat Ahmed, PhD - Head Integrated Drug Discovery, Aurigene Pharmaceutical Services
              Spotlight Presentations
              13:25 - 13:5530 mins
              Spotlight Presentation 1
              Achieving Control in Oligo Manufacturing: Innovations, Strategies, and Technologies
              • Cory Hinz - Engineering Manager, Asahi Kasei Bioprocess
              • Thomas Rupp - Owner & Principal, Thomas Rupp Consulting AG
              13:25 - 13:5530 mins
              Spotlight Presentation 2
              Bridging the Translational Chasm in Oligonucleotide/Peptide Programs: A Convergence Framework in Propelling Novel Modalities from Lead Optimization to GMP Readiness
              • William Fang - Vice President of Oligonucleotide and Peptide Development, WuXi TIDES
              13:25 - 13:5530 mins
              Spotlight Presentation 3
              Purification of Oligonucleotides Using Reverse Phase and Anion Exchange Resins
              • Sophie Corbet - EMEA Bioprocessing Technical Service Manager, DuPont
              13:55 - 14:005 mins
              Oligonucleotide Discovery, Preclinical and Clinical
              Chairman's Remarks: Oligonucleotide Preclinical and Clinical Updates
                13:55 - 14:005 mins
                Oligonucleotide Chemistry, Manufacturing & Controls
                Chairman's Remarks: Analytical and CMC Strategies for Oligonucleotides
                • Mike Webb, Ph.D. - Founder and CEO, Mike Webb Pharma
                13:55 - 14:005 mins
                Peptide Discovery to CMC
                Chairman’s Remarks: Innovations and New Technologies in Peptide CMC
                  14:00 - 14:3030 mins
                  Oligonucleotide Discovery, Preclinical and Clinical
                  Delivering Beyond Promises: Oligonucleotide Therapeutics as Best-in-Class Medicines
                  • Chris Hart, PhD - VP, Data Science and AI/ML, Eli Lilly and Company
                  14:00 - 14:3030 mins
                  Oligonucleotide Chemistry, Manufacturing & Controls
                  A New Strategy for Diastereomer Profiling: The Overlapping Fragment Approach
                  • Matthew Quinn - Manager, Analytical Development, Global Nucleic Acid Therapies, Novo Nordisk
                  14:00 - 14:3030 mins
                  Peptide Discovery to CMC
                  Tag-Assisted Peptide Synthesis (TAPS) - Development of a Continuous Liquid-Phase Process
                  • Andreas Heindl, PhD - Innovation Team Lead, Corden Pharma
                  14:30 - 15:0030 mins
                  Oligonucleotide Discovery, Preclinical and Clinical
                  ETX-312 - A Novel GalOmic GalNAc-siRNA for the Treatment of MASH
                  • Alan Whitmore - Chief Scientific Officer, e-therapeutics
                  14:30 - 15:0030 mins
                  Oligonucleotide Chemistry, Manufacturing & Controls
                  Nitto Avecia Oligonucleotide CMC Presentation
                    14:30 - 15:0030 mins
                    Peptide Discovery to CMC
                    PolyPeptide’s Approach to Process Intensification: Tackling the increasing Peptide Demand
                    • Fabien Rousset, PhD - Global Director of Innovation, Polypeptide Group
                    15:00 - 15:3030 mins
                    Oligonucleotide Discovery, Preclinical and Clinical
                    Continuing to deLIVER; Novel Genetically Validated Hepatocyte Targets Fueling the Alnylam Pipeline
                    • Paul Nioi, PhD - SVP, Alnylam Pharmaceuticals, Inc.
                    15:00 - 15:3030 mins
                    Oligonucleotide Chemistry, Manufacturing & Controls
                    Characterization of Partially Phosphorothiolated Oligonucleotides: Analytical Strategies for CMC Support
                    • Leo Joyce, phD - Director, Analytical Department, Arrowhead Pharmaceuticals
                    15:00 - 15:3030 mins
                    Peptide Discovery to CMC
                    Bachem Peptide CMC Presentation
                      15:30 - 16:1545 mins
                      Networking Refreshment Break in Poster and Exhibit Hall
                      Networking Refreshment Break in Poster and Exhibit Hall
                        16:15 - 16:4530 mins
                        Oligonucleotide Discovery, Preclinical and Clinical
                        First-in-human Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA Drug Targeting Coagulation Factor XI (FXI), in Healthy Subjects
                        • Anders Gabrielsen, PhD - VP - Head of Global Clinical Development, Ribocure Pharmaceuticals
                        16:15 - 16:4530 mins
                        Oligonucleotide Chemistry, Manufacturing & Controls
                        Navigating Analytical Challenges in siRNA Fixed-Dose Combinations: A Comprehensive Approach
                        • Alessandro Sannino, PhD - Senior Expert Science and Technology, Novartis
                        16:15 - 16:4530 mins
                        Peptide Discovery to CMC
                        Biopharmaceutical Production of Next Generation Peptides
                        • Bernd Mitic, PhD - Post Doctoral Scientist, Boehringer Ingelheim
                        16:45 - 17:1530 mins
                        Oligonucleotide Discovery, Preclinical and Clinical
                        Transfer of ASO Therapy into Clinical Epileptology: Lessons Learned
                        • Ingo Borggräfe, M.D - Pediatric Neurologist, University of Munich
                        16:45 - 17:1530 mins
                        Oligonucleotide Chemistry, Manufacturing & Controls
                        Challenges for Oligo UHPLC Method Transfer: Balancing Resolution & Equipment Complexity to Streamline Analytical Method Transfer to Different Sites
                        • Huijun Tian, PhD - Director of Analytical Development and Quality Control, QurAlis Corporation
                        16:45 - 17:1530 mins
                        Peptide Discovery to CMC
                        Peptide CMC Strategies
                        • Mette Husbyn - CMC Manager, Lytix Biopharma, Norway
                        17:15 - 19:30135 mins
                        Evening Networking Reception
                          19:30 - 19:355 mins
                          Close of Day Two

                            * 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

                            Pre-Conference Workshops (am) & Main Conference Day 1 Plenary (pm)
                            Next Main Conference Day 3